Trials / Terminated
TerminatedNCT05047640
COVID-19 3rd Dose Vaccine in Transplant Patients
A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Giselle Guerra · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BNT162b2 vaccine | Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle |
| BIOLOGICAL | JNJ-78436735 Vaccine | Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle |
Timeline
- Start date
- 2021-09-14
- Primary completion
- 2022-10-25
- Completion
- 2022-10-25
- First posted
- 2021-09-17
- Last updated
- 2024-06-04
- Results posted
- 2023-06-22
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05047640. Inclusion in this directory is not an endorsement.